CPA
ACHV icon

Capital Performance Advisors’s Achieve Life Sciences ACHV Stock Holding History

Capital Performance Advisors’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-77
Closed -$365 – 191
2024
Q3 		$365 Buy
+77
New +$352 ﹤0.01% 2391

Other funds holding ACHV

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Performance Advisors's ACHV Position: Q4 2024 in Review

Capital Performance Advisors sold out of Achieve Life Sciences (ACHV) in Q4 2024, closing a stake of 77 shares — an estimated $365 sold.

Capital Performance Advisors first reported a position in ACHV in Q3 2024 and held it in 1 quarter. The position peaked at $365 in Q3 2024. 70 funds tracked by Wall St. Rank hold ACHV as of Q4 2024.

  • Capital Performance Advisors reported no remaining Achieve Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 77 Achieve Life Sciences shares in Q4 2024, an estimated $365.
  • Capital Performance Advisors first reported a position in Achieve Life Sciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Achieve Life Sciences position peaked at $365 in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.